Sunrise, FL – October 10, 2017 – (OTC:USRM) U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, announced today that its Chief Science Officer Kristin Comella, PhD, will present on October 13 th at Bulletproof’s 5 th Annual Biohacking Conference in Pasadena, CA. Dr. Comella’s presentation will be live- streamed, starting at 3:15 p.m. PT via Facebook Live on the U.S. Stem Cell, Inc. Facebook Page at https://www.facebook.com/USStemCellInc/.
Dr. Comella’s participation is part of U.S. Stem Cell, Inc.’s ongoing effort to educate consumers on the power of using their body’s own healing potential through regenerative medicine. At the Biohacking Conference, Dr. Comella will be joining an informational Stem Cell Panel led by Harry Adelson, ND, an expert in stem cell therapy and the founder of Docere Clinics in Park City, Utah. This will be Dr. Comella’s second consecutive appearance at the Biohacking Conference.
Dr. Comella’s invitations to speak at the Bulletproof Conference follow a stem cell treatment Bulletproof Founder Dave Asprey received at U.S. Stem Cell Clinic back in July 2016, when he live-streamed the procedure on Facebook. U.S. Stem Cell Clinic is 33.3% owned by U.S. Stem Cell, Inc. To watch the recoded version of Asprey’s Facebook Live video, click here: https://tinyurl.com/y7vjqwfd.
Dr. Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin’s list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, Dr. Comella made the list of Top 50 Functional and Integrative Medical Doctors in the country by DrAxe.com, one of the most visited natural health websites in the world.
“I am excited and honored to be a part of the Bulletproof Conference that brings together some of the brightest minds in the regenerative industry who are pushing the limits of what the human mind and body can do,” Dr. Comella said in a statement. “Please tune in on Facebook Live at 3:15 pm PT on October 13 th to watch the stem cell panel discussion.”
U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. Since 1999, the company has completed more clinical treatments (for both humans and animals) than any other regenerative company in the world. U.S. Stem Cell, Inc. is focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. U.S. Stem Cell, Inc. has also partnered with other companies to build a national distribution network for stem cell therapies using the U.S. Stem Cell, Inc. developed technologies and is on track to add an additional 10 stem cell treatment centers and clinics in the U.S.
About U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine /cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine/ cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward- looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors”; in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.